ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial
Patients with recurrent platinum-resistant ovarian cancer (PROC) have poor clinical outcomes, owing mainly to the presence of therapy-resistant cancer stem cells (CSCs). The NCT03949283 randomized clinical trial enrolled patients with recurrent PROC to receive ChemoID-guided chemotherapy or the best physician-choice regimen selected from the same list of thirteen mono or combination chemotherapies. The primary outcome was objective response rate (ORR) assessed on CT scans using the RECIST 1.1 criteria at 6 months follow-up. Subjects treated with the ChemoID assay had an ORR of 55% (CI<sub>95</sub> 39% - 73%), compared to 5% (CI<sub>95</sub> 0% - 11%) for those treated with physician's choice chemotherapy (p <0.0001). Secondary endpoints of duration of response (DOR) and progression-free survival (PFS) of subjects treated with chemotherapies guided by the ChemoID assay versus physician's choice chemotherapy were a median of 8 months vs. 5.5 months (p <0.0001), and 11.0 months (CI<sub>95</sub> 8.0- NA) vs 3.0 months (CI<sub>95</sub> 2.0- 3.5) with 27% of hazard ratio (CI95, 0.15-0.49; p <0.001), respectively.
Authors
- Thomas C. Krivak
- John P. Diaz (ORCID: https://orcid.org/0000-0002-4364-5824)
- Pier Paolo Claudio (ORCID: https://orcid.org/0000-0001-7790-1622)
- Abhijit Barve (ORCID: https://orcid.org/0000-0002-2070-3147)
- Scott E. Lentz (ORCID: https://orcid.org/0000-0002-9435-2570)
- Candace M. Howard (ORCID: https://orcid.org/0000-0001-6537-3551)
- Stephen Bush (ORCID: https://orcid.org/0000-0002-3679-7256)
- Nadim Bou Zgheib (ORCID: https://orcid.org/0000-0001-6163-9009)
- Jagan Valluri
- Navya Nair (ORCID: https://orcid.org/0000-0002-5223-4808)
- Krista L. Denning (ORCID: https://orcid.org/0000-0002-2632-2230)
- Camille Gunderson-Jackson
- Seth T. Lirette (ORCID: https://orcid.org/0000-0003-2603-6071)
- Thomas J. Herzog (ORCID: https://orcid.org/0000-0002-4584-8908)
Institutions
- Louisiana State University (US)
- Baptist Hospital of Miami (US)
- Allegheny Health Network (US)
- Charleston Area Medical Center (US)
- Kaiser Permanente (US)
- University of Miami (US)
- Huntington University (US)
- Jackson Memorial Hospital (US)
- University of Mississippi Medical Center (US)
- Mercy Clinic Neurology (US)
- Los Angeles Medical Center (US)
- Baptist Health South Florida (US)
- Psychogenics (United States) (US)
- Edwards Comprehensive Cancer Center (US)
- Sylvester Comprehensive Cancer Center (US)
- Tris Pharma (United States) (US)
- University of Oklahoma Health Sciences Center (US)
- University of Cincinnati (US)
- Marshall University (US)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1038/s41698-025-00874-0
- Citations
- 2
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.40